Why did Supriya Lifesciences (SUPRIYA) stock move recently?

On 8/4/2026, Supriya Lifesciences moved +3.2% — No specific company catalyst or news identified for the move; Supriya Lifesciences rose with broader market or sector trends. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Supriya Lifesciences (SUPRIYA) overvalued or fairly valued?

MarketChacha shows Supriya Lifesciences's valuation in context — a forward P/E of about 20.4, a price-to-book of about 5.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Supriya Lifesciences's revenue?

Supriya Lifesciences reported revenue of ₹828 Cr for FY2026, with net profit of ₹209 Cr, per official filings.

What is the share price of Supriya Lifesciences (SUPRIYA)?

Supriya Lifesciences last traded at ₹791.65 (-4.7% on the day), as of 8/14/2026 — a delayed quote shown for education, not investment advice.

Supriya Lifesciences

SUPRIYA · NSE · Pharma · India

Snapshot

TickerSUPRIYA

ExchangeNSE

SectorPharma

IndustryBiotechnology

CountryIndia

HeadquartersMumbai, India

Websitewww.supriyalifescience.com

Filings tracked0

About Supriya Lifesciences

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Who owns it

Promoters71.3%
Institutions4.8%
Public & other23.9%

19 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend19.5% → 25.3%

Margin has expanded by about 5.8 points — the business is getting more profitable.

Growth qualityrev 16% · PAT 24%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next fiscal year

Rev ₹1,242 Cr · EPS 4.10

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹828 Cr

Net margin

25.3%

Revenue CAGR (3y)

+21.6%

Profit CAGR (3y)

+32.5%

Net profit (FY2026)

₹209 Cr

Ask MarketChacha about SUPRIYA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
No specific company catalyst or news identified for the move; Supriya Lifesciences rose with broader market or sector trends.
· confidence: low
Jul 29, 2026
No clear company-specific catalyst identified in recent credible coverage; the stock rose with broader market or sector momentum.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹828 Cr	₹209 Cr	25.3%
FY2025	₹696 Cr	₹188 Cr	27.0%
FY2024	₹570 Cr	₹119 Cr	20.9%
FY2023	₹461 Cr	₹90 Cr	19.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹190 Cr	₹24 Cr	2.99	12.7%
Q4 FY26	₹277 Cr	—	—	—
Q3 FY26	₹206 Cr	—	—	—
Q1 FY26	₹145 Cr	₹35 Cr	—	24.0%
Q3 FY25	₹186 Cr	—	—	—

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.